Filing Details
- Accession Number:
- 0001104659-10-043319
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-08-10 13:00:00
- Reporting Period:
- 2010-08-06
- Filing Date:
- 2010-08-10
- Accepted Time:
- 2010-08-10 06:03:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1356857 | Trius Therapeutics Inc | TRSX | Pharmaceutical Preparations (2834) | 201320630 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1356809 | Kpcb Pandemic & Bio Defense Fund Llc | C/O Kleiner Perkins Caufield &Amp; Byers 2750 Sand Hill Road Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-08-06 | 1,055,581 | $0.00 | 1,055,581 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2010-08-06 | 498,394 | $0.00 | 1,553,975 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2010-08-06 | 823,906 | $5.00 | 2,377,881 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2010-08-06 | 9,078,000 | $0.00 | 1,055,581 | $0.00 |
| Common Stock | 8% Convertible Promissory Note | Disposition | 2010-08-06 | 498,394 | $0.00 | 498,394 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Series B Preferred Stock was converted into shares of the Issuers Common Stock upon the consummation on the Issuer's initial Public Offering on an 8.6 for 1 basis.
- Principal and accrued interest was converted upon the Issuer's initial public offering into shares of Common Stock at a conversion price of 87.5% of the per share price of the Common Stock sold in the Issuer's initial public offering on August 6, 2010, at $5.00 per share.
Billionaire Hedge Funds
